New psychoactive substances in Europe: Legislation and prosecution – current challenges and solutions

by Virve Toivanen-Schagen, Patricia Pinto,  Brendan Hughes et al.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Eurojust, November 2016

30 pp. 435 kB
http://www.emcdda.europa.eu/system/files/publications/3353/TD0416736ENN.pdfpic-003_resize

Europe is fighting a battle against dangerous designer drugs being created so fast and frequently that authorities are struggling to control them, EU agencies say in this report . Nearly 300 such drugs hit European markets between 2013 and 2015 alone, according to the report by the two agencies, which warned of a particular problem with synthetic cannabinoid products crafted to mimic the chemical make-up of cannabis. The evolution of the European market for NPS (“new psychoactive substances”) has accelerated to a speed that the public authorities’ established response – drug control laws – has struggled to match, said the European Monitoring Centre for Drugs and Drug Addiction and judicial cooperation agency Eurojust.

(Visited 34 times, 1 visits today)
This entry was posted in General, Harm Reduction & Drug Use. Bookmark the permalink.